Zhengye Biotechnology Holding (ZYBT) Debt Ratio (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) reported Debt Ratio of 0.17 for Q4 2025, up 5.46% year-over-year from 0.16 in Q4 2024, and up 1661.77% quarter-over-quarter from 0.01 in Q2 2025.

Zhengye Biotechnology Holding (ZYBT) Debt Ratio (2023 - 2025) Analysis & Trends

Zhengye Biotechnology Holding (ZYBT) has 3 years of Debt Ratio data on file, last reported at 0.17 in Q4 2025.

  • Debt Ratio for Q4 2025 came in at 0.17, up 5.46% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.17 (up 5.46% YoY), and the FY2025 annual result was 0.16, up 2.62% from the prior year.
  • Debt Ratio grew to 0.17 in Q4 2025 per ZYBT's latest filing, from 0.01 in the prior quarter.
  • Over five years, Debt Ratio peaked at 0.17 in Q4 2025 and troughed at 0.01 in Q2 2025.
  • A 3-year average of 0.13 and a median of 0.16 in 2023 frame the typical range for Debt Ratio.
  • The sharpest annual moves came in 2024 and 2025: Debt Ratio increased 0.07% in 2024, then advanced 5.46% in 2025.
  • A 3-year view of Debt Ratio shows it stood at 0.16 in 2023, then grew by 0.07% to 0.16 in 2024, then rose by 5.46% to 0.17 in 2025.
  • Business Quant data shows ZYBT's Debt Ratio at 0.17 in Q4 2025, 0.01 in Q2 2025, and 0.16 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 0.42
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 0.60
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 0.01
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 0.30
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 0.35
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 0.24
10 Zhengye Biotechnology Holding 5.49 Mn 6.20 Mn - 0.17

Historic Data

Download Data
DateValue
Dec 31, 2025 0.17
Jun 30, 2025 0.01
Dec 31, 2024 0.16
Dec 31, 2023 0.16